Life Sciences Drug Delivery Technologies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Drug Delivery Technologies
1.1 - About Life Sciences Drug Delivery Technologies sector
Companies in the Life Sciences Drug Delivery Technologies category design and supply platforms that optimize how therapeutics are formulated, transported, and released. For analysts profiling strategic buyers in drug delivery technologies, these vendors enable improved bioavailability, targeted tissue access, and patient-friendly administration across small molecules, biologics, and RNA medicines. By combining formulation science with drug‑device integration and scalable manufacturing, they help sponsors advance pipelines and extend product life cycles.
Typical offerings span controlled‑release and sustained‑release formulations, lipid nanoparticle and polymeric nanoparticle carriers for RNA and biologics, liposomal encapsulation, and oral solid dose optimization. Many provide transdermal patches, microneedle arrays, and inhalation or intranasal delivery platforms, alongside implantable depots for long‑acting therapies. Vendors also develop drug‑device combination systems such as auto‑injectors and prefilled syringes, plus targeting ligands and excipient systems to tune pharmacokinetics and tissue specificity. Many also provide CMC support and GMP scale‑up services.
Primary customers include pharmaceutical sponsors, biotech developers, and contract development and manufacturing organizations. These providers enable higher bioavailability and efficacy, improved patient adherence through easier administration and reduced dosing frequency, and differentiation via novel delivery profiles that can extend market exclusivity. They also support manufacturability and regulatory compliance, accelerating preclinical-to-clinic transitions and de-risking scale‑up for commercial launch.
2. Buyers in the Life Sciences Drug Delivery Technologies sector
2.1 Top strategic acquirers of Life Sciences Drug Delivery Technologies companies
MannKind
- Description: Provider of inhaled therapeutic medicines that develop, manufacture and commercialize dry-powder treatments such as Afrezza rapid-acting mealtime insulin, leveraging its proprietary Technosphere drug-delivery platform for rapid, deep-lung delivery to address diseases like diabetes and pulmonary arterial hypertension.
- Key Products:
- Dry-Powder Drug Formulations: Converts active pharmaceutical ingredients into respirable powders that enable rapid pulmonary delivery, achieving fast systemic absorption or local lung action and reducing injection requirements
- Inhalation Delivery Devices: Proprietary handheld inhalers engineered to disperse dry-powder medicines deep into the lungs, providing convenient, on-demand dosing with minimal patient training
- Inhaled Insulin Therapy: Ultra-rapid-acting insulin delivered via MannKind’s dry-powder inhaler to improve post-prandial glucose control for people with diabetes while eliminating multiple daily injections
- Clofazimine Inhalation Suspension (ICoN-1): Investigational aerosolized clofazimine formulation in Phase 3 trials designed to treat nontuberculous mycobacterial lung disease by achieving high pulmonary drug concentrations with limited systemic exposure.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Drug Delivery Technologies sector
M&A buyer group 1: Drug Delivery Patches
CeQur
- Type: N/A
- Employees: ●●●●●
- Description: Provider of a wearable insulin delivery patch that enables injection-free, on-demand mealtime and correction bolus dosing. The thin, lightweight device uses a flexible cannula and one-click 2-unit dosing to replace multiple daily injections, reduce pain, and improve glucose control for people with diabetes.
- Key Products:
- CeQur Simplicity: Wearable 4-day insulin patch that stores 200 units of rapid-acting insulin, delivers two-unit bolus doses on demand, and replaces roughly twelve daily injections, offering discreet, needle-free mealtime control
- CeQur Cares Program: Clinical support service providing welcome calls, three-step training, patch change guidance and ongoing check-ins to ensure patients and clinicians successfully adopt and use CeQur Simplicity.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Drug Delivery Technologies sector
3.1 - Buyout funds in the Life Sciences Drug Delivery Technologies sector
2.2 - Strategic buyer groups for Life Sciences Drug Delivery Technologies sector
4 - Top valuation comps for Life Sciences Drug Delivery Technologies companies
4.2 - Public trading comparable groups for Life Sciences Drug Delivery Technologies sector
Valuation benchmark group 1: Injectable Drug Delivery Manufacturers
Stevanato Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of integrated systems, processes, and services for the pharmaceutical and healthcare industries, specializing in glass primary packaging, drug delivery devices, and assembly and packaging equipment. Offers comprehensive solutions to ensure the integrity and safety of medications through advanced technologies and engineering excellence.
- Key Products:
- Precision Glass Forming: Advanced glass forming lines for pharmaceutical packaging
- Vision Inspection Systems: Equipment for inspecting drug containment solutions
- Drug Delivery Devices: Production of autoinjectors, pen injectors, and wearable injectors
- Assembly and Packaging: Solutions for efficient assembly and packaging of medical products
- Pre-Sterilized Containers: EZ-fill® technology for ready-to-use drug packaging solutions.